wednesday 4:30 PM 2168. ALD518 (BMS945429), a High Affinity Monoclonal Antibody Directed Against Interleukin-6, Reduces Disease Activity and Achieves Remission in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate. Philip Mease 5 , Vibeke Strand 4 , Levan Shalamberidze 6 , Aleksandar Dimic 3 , Richard Aranda 2 and Jeff Smith 1 , 1 Alder Biopharmaceuticals Inc., Bothell, WA, 2 Bristol-Myers Squibb, Princeton, NJ, 3 Institute <strong>of</strong> Rehabilitation and Treatment, Niska Banja, Serbia, 4 Stanford University, Palo Alto, CA, 5 Swedish Medical Center and University <strong>of</strong> Washington, Seattle, WA, 6 V. Tsitlanadze Scientific Practical Centre <strong>of</strong> <strong>Rheumatology</strong>, Tbilisi, Georgia 4:45 PM 2169. Efficacy and Safety <strong>of</strong> Ocrelizumab in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One TNF Inhibitor: Results from the Phase III SCRIPT Trial. Paul P. Tak 1 , Philip J. Mease 7 , Mark C. Genovese 8 , Joel M. Kremer 9 , Boulos Haraoui 4 , Yoshiya Tanaka 10 , Clifton O. Bingham 5 , Ali Ashrafzadeh 2 , Helen Travers 6 , Simon Safa-Leathers 6 , Sanjeev Kumar 6 and Wolfgang Dummer 3 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Genentech, San Francisco, CA, 3 Genentech, 4 Institut de Rhumatologie, Montreal, QC, Canada, 5 Johns Hopkins University, Baltimore, MD, 6 Roche, 7 Seattle <strong>Rheumatology</strong> Associate, Seattle, WA, 8 Stanford Univ, Sunnyvale, CA, 9 The Center for <strong>Rheumatology</strong>, Albany, NY, 10 U Occupa & Environ Hlth, Kitakyushu, Japan 5:00 PM 2170. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy <strong>of</strong> the Monoclonal Antibody ASK8007 Blocking Osteopontin in Patients with Rheumatoid Arthritis in a Randomized, Placebo-Controlled, Combined Firstin-Man and Pro<strong>of</strong>-<strong>of</strong>-Concept Study. M. Boumans 5 , J. Houbiers 1 , P. Verschueren 10 , A. Ishikura 2 , R. Westhovens 10 , E. Brouwer 4 , B. Rojkovich 8 , S. Kelly 3 , M. Den Adel 2 , J. Isaacs 7 , J. Gomez-Reino 9 , G. Holtkamp 2 , D. Gerlag 6 and P. Tak 6 , 1 Astellas Pharma Global Development, the Netherlands and Japan, Leiderdorp, The Netherlands, 2 Astellas Pharma Global Development, the Netherlands and Japan, 3 Centre for Experimental Medicine and <strong>Rheumatology</strong>, Queen Mary’s School <strong>of</strong> Medicine, London, 4 Department <strong>Rheumatology</strong>, University Medical Center Groningen, Groningen, The Netherlands, 5 Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical Center / University <strong>of</strong> Amsterdam, Amsterdam, Noord-Holland, The Netherlands, 6 Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical Center / University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 7 Musculoskeletal Research Group, Institute <strong>of</strong> Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 8 <strong>Rheumatology</strong>, Buda Charity Hospital, Budapest, Hungary, 9 <strong>Rheumatology</strong>, Hospital Clinico Universitario, Santiago de Compostela, Spain, Santiago, Spain, 10 University Hospital Leuven, Leuven, Belgium 5:15 PM 2171. Tasocitinib (CP-690,550) Appears To Be Effective and Tolerated When Administered Either as Long-Term Monotherapy or on Background Methotrexate in Patients with Rheumatoid Arthritis. Carol A. Connell 1 , Richard Riese 2 , Susan Wood 2 , John Bradley 2 and Samuel H. Zwillich 2 , 1Pfizer Inc, New London, CT, 2 Pfizer Inc. 5:30 PM 2172. A Randomized Dose-Ranging, Placebo-Controlled Study <strong>of</strong> INCB028050, a Selective JAK1 and JAK2 Inhibitor in Subjects with Active Rheumatoid Arthritis. Maria W. Greenwald 1 , Rosanne Fidelus-Gort 4 , Rich Levy 4 , Jinjin Liang 4 , Kris Vaddi 4 , William V. Williams 3 , Robert Newton 4 , Swamy Yeleswaram 4 , Robert Flores 4 , Edward McKeever 4 , James Rodgers 4 , Stacey Shepard 4 , Pierre-Yves Berclaz 2 , Chin Hyok Lee 2 and Monica E. Luchi 3 , 1 Desert Medical, Palm Desert, CA, 2 Eli Lilly & Company, 3 Incyte Corporation, Wilmington, DE, 4 Incyte Corporation 5:45 PM 2173. A Large, Phase IIIb Non-Inferiority Trial <strong>of</strong> Subcutaneous (SC) Abatacept Compared with Intravenous (IV) Abatacept, in Patients with Rheumatoid Arthritis (RA). Mark C. Genovese 13 , Jose Arturo Covarrubias 3 , Gustavo Leon 5 , Eduardo F. Mysler 8 , Mauro W. Keiserman 10 , Robert M. Valente 9 , Peter Nash 15 , J. Abraham Simon 2 , Wieslawa Porawska 11 , Jane H. Box 14 , Clarence W. Leggerton 6 , Evgeny Nasonov 7 , Patrick Durez 4 , Richard Aranda 1 , Ramesh Pappu 1 , Ingrid Delaet 1 , Julie Teng 1 and Rieke Alten 12 , 1 Bristol-Myers Squibb Co, Princeton, NJ, 2 Centro de Especialidades Médicas, Merida, Mexico, 3 Centro Medico de Las Americas, Merida, Yucatan, Mexico, 4 Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, 5 De Ginecologia Y Reproduccion, Lima, Peru, 6 Department <strong>of</strong> Medicine, Medical University <strong>of</strong> South Carolina, Charleston, SC, 7 Institute <strong>of</strong> <strong>Rheumatology</strong>, Moscow, Russia, 8 Organización Médica de Investigación, Buenos Aires, Argentina, 9 Physician Research Collaboration, Lincoln, Lincoln, NE, 10 Pontificial Catholic University, School <strong>of</strong> Medicine, Porto Alegre, Brazil, 11 Poznanski Osrodek Medyczny Novamed, Ponzan, Poland, 12 Schlosspark- Klinik, Charité, University Medicine Berlin, Department <strong>of</strong> Internal Medicine II <strong>Rheumatology</strong>, Berlin, Germany, 13 Stanford University, Palo Alto, Sunnyvale, CA, 14 The Arthritis Clinic & Carolina Bone & Joint, Charlotte, NC, 15 University <strong>of</strong> Queensland, Brisbane, Australia A406 Sjögren’s Syndrome Moderators: Alan N. Baer, MD; Johns Hopkins University; Baltimore, MD Athanasios G. Tzioufas, MD; Medical School-University <strong>of</strong> Athens; Athens, Greece 4:30 PM 2174. Receptor-Mediated Small Interfering RNA Delivery in Sjögren’s Syndrome. Kaleb M. Pauley, Adrienne E. Gauna and Seunghee Cha, University <strong>of</strong> Florida, Gainesville, FL 4:45 PM 2175. Structure and Antigenicity <strong>of</strong> the Ro/La RNP Particle. hY1 RNA Differentiates the Recognition <strong>of</strong> Epitopes in Systemic Lupus Erythematosus and Sjögren’s Syndrome. John G. Routsias1, Nikos C. Kyriakidis 1 , Stathis Kotsakis 1 and Athanasios G. Tzioufas 2 , 1 Department <strong>of</strong> Pathophysiology, Medical School, University <strong>of</strong> Athens, Athens, Greece, 2 Medical School-Univ <strong>of</strong> Athens, Athens, Greece 126 2010 Program Book
5:00 PM 2176. A Role <strong>of</strong> Autoimmune Response to M3 Muscarinic Acethylcholine Receptor in the Pathogenesis <strong>of</strong> Sjögren’s Syndrome Like Autoimmune Sialoadenitis. Mana Iizuka 2 , Hiroto Tsuboi 2 , Yumi Nakamura 2 , Naomi Matsuo 2 , Isao Matsumoto 2 and Takayuki Sumida 1 , 1 Univ <strong>of</strong> Tsukuba/Inst Clin Med, Tsukuba City, Japan, 2 Univ <strong>of</strong> Tsukuba/Inst Clin Med 5:15 PM 2177. Δ4BAFF, an Alternate-Splice Is<strong>of</strong>orm That Acts as a Transcription Factor To Enhance BAFF Production in Primary Sjögren’s Syndrome. Jacques-Olivier Pers, Gabriel J. Tobon, Laëtitia Le Pottier and Pierre Youinou, Brest University, Brest, France 5:30 PM 2178. Local TACI-Ig Gene Therapy <strong>of</strong> the Salivary Gland <strong>of</strong> NOD Mice Reduces Auto-Immune Inflammation by Affecting the B Cell Compartment. Nienke Roescher 2 , Jelle L. Vosters 2 , Marco Guadagnoli 2 , Jan P. Medema 2 , Gabor G. Illei 4 , John A. Chiorini 3 and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical Center-University <strong>of</strong> Amsterdam, 3 National Insitutes <strong>of</strong> Health-National Institute <strong>of</strong> Dental and Crani<strong>of</strong>acial Research, 4 NIDCR, NIH #10 1N114, Bethesda, MD 5:45 PM 2179. EBV-mir-Bart13 Downregulates Stim1, a Protein Involved in Calcium Signaling, in Human Salivary Gland Cells and May Contribute to the Pathogenesis <strong>of</strong> Sjögren’s Syndrome. Alessia Gallo 1 , Mayank Tandon 1 , Gabor G. Illei 2 and Ilias Alevizos 1 , 1 National Insitutes <strong>of</strong> Health-National Institute <strong>of</strong> Dental and Crani<strong>of</strong>acial Research, 2 NIDCR, NIH #10 1N114, Bethesda, MD A311 Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment - Biomarkers II Moderators: Daniel O. Clegg, MD; University <strong>of</strong> Utah Medical Center; Salt Lake City, UT Robert Landewe, MD; University Hospital Maastricht; Maastricht, The Netherlands 4:30 PM 2180. Striking Prevalence <strong>of</strong> Axial Spondyloarthritis in Primary Care Patients with Chronic Low Back Pain; a Cross-Sectional Study. Lonneke van Hoeven 3 , Jolanda Luime 1 , Huub Han 2 and Angelique Weel 4 , 1 Erasmus Medical Centre, 2 Maasstadziekenhuis, 3 Maasstadziekenhuis / Erasmus Medical Centre, Rotterdam, The Netherlands, 4 Maasstadziekenhuis Rotterdam, Rotterdam, The Netherlands 4:45 PM 2181. Screening for Axial Spondyloarthritis in a Primary Care: Comparison <strong>of</strong> Two Strategies in a Multicenter Prospective Study. Denis Poddubnyy 1 , Janis Vahldiek 1 , Inge Spiller 1 , Beate Buss 1 , Martin Rudwaleit 1 and Joachim Sieper 2 , 1 Charité - Campus Benjamin Franklin, Berlin, Germany, 2 Charite Campus Benjamin Frankl, Berlin, Germany 5:00 PM 2182. Do the New EULAR/ACR Rheumatoid Arthritis Classification Criteria Identify Early Psoriatic Arthritis Patients? Laura C. Coates 2 , Philip G. Conaghan 2 , Paul Emery 2 , Michael J. Green 3 , Gamal Ibrahim 1 , Helen MakIver 1 and Philip S. Helliwell 2 , 1 Bradford Hospitals NHS Trust, UK, Bradford, United Kingdom, 2 LIMM, Section <strong>of</strong> Musculoskeletal Disease, University <strong>of</strong> Leeds, Leeds, UK, 3 York Hospitals NHS Trust, York, UK 5:15 PM 2183. The CASPAR Criteria Can Be Used To Identify Early Psoriatic Arthritis. Laura C. Coates 2 , Philip G. Conaghan 3 , Paul Emery 3 , Michael J. Green 4 , Gamal Ibrahim 1 , Helen MakIver 1 and Philip S. Helliwell 3 , 1 Bradford Hospitals NHS Trust, UK, Bradford, United Kingdom, 2 LIMM, Section <strong>of</strong> Musculoskeletal Disease, University <strong>of</strong> Leeds, Leeds, United Kingdom, 3 LIMM, Section <strong>of</strong> Musculoskeletal Disease, University <strong>of</strong> Leeds, UK, 4 York Hospital NHS Trust, York, UK 5:30 PM 2184. Supppression <strong>of</strong> Both DKK-1 and SOST in a Mouse Model <strong>of</strong> Ankylosing Spondylitis Implicates the WNT-Signalling Pathway in the Linkage <strong>of</strong> Inflammation and Bony Ankylosis in Spondyloarthritis. Gethin P. Thomas 2 , Ran Duan 3 , Allison Pettit 4 , Tibor Glant 1 and Matthew A. Brown 2 , 1 Rush University Medical Center, 2 The University <strong>of</strong> Queensland Diamantina Institute, 3 The University <strong>of</strong> Queensland Diamantina Institute, 4 University <strong>of</strong> Queensland Centre for Clinical Research 5:45 PM 2185. Genetic and Clinical Correlates in African <strong>American</strong>s with Ankylosing Spondylitis. Shervin Assassi 4 , Julie T. Dang 3 , Michael M. Ward 2 , Joel D. Taurog 6 , Michael H. Weisman 1 and John D. Reveille 5 , 1 Cedars- Sinai Medical Center, Los Angeles, CA, 2 NIH, NIAMS, IRP, Bethesda, MD, 3 Univ <strong>of</strong> Texas Health Science Center at Houston, 4 Univ <strong>of</strong> Texas Health Science Center at Houston, Houston, TX, 5 Univ Texas Health Sci Ctr, Houston, TX, 6 U-Texas SW Med Ctr, Dallas, TX A315 Systemic Lupus Erythematosus - Animal Models Moderators: Philip L. Cohen, MD; Temple University; Philadelphia, PA Jane E. Salmon, MD; Hospital for Special Surgery; New York, NY 4:30 PM 2186. Neutrophil Gelatinase Associated Lipocalin (NGAL) and Its Role in the Pathogenesis <strong>of</strong> Nephritis Induced by Pathogenic Antibodies. Rahul Pawar 4 , Simona Gindea 4 , Arlene T. Tieng 3 , MIlena Pitashny 4 , Leal Herlitz 5 , Benjamin E. Levine 2 , Thorsten Berger 6 , Tak W. Mak 6 and Chaim Putterman 1 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Med, Bronx, NY, 2 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, Woodmere, NY, 3 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, Bronx, NY, 4 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, 5 Columbia-Presbyterian School <strong>of</strong> Medicine, 6 The Campbell Family Institute for Breast Cancer Research, Toronto, ON, Canada wednesday 2010 Program Book 127
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78: 2:45 PM 1405. Development of a Visi
- Page 79 and 80: 4:30 PM Anti-citrullinated Protein
- Page 81 and 82: of Experimental Orthopedics, Univer
- Page 83 and 84: 5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86: 5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88: Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90: 7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92: • compare the prevalence and epid
- Page 93 and 94: 6:45 PM Macrophage Activation Syndr
- Page 95 and 96: Upon completion of this session, pa
- Page 97 and 98: Session Overview: This roundtable d
- Page 99 and 100: B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102: 9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104: • describe the role of IL-1 and I
- Page 105 and 106: Session Overview: For the clinician
- Page 107 and 108: • identify the aspects for day-to
- Page 109 and 110: ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112: Session Overview: Ultrasound and ma
- Page 113 and 114: Session Overview: Fifty percent of
- Page 115 and 116: 1:20 PM Academic Rheumatology Seth
- Page 117 and 118: ACR Concurrent Abstract Sessions 2:
- Page 119 and 120: 3:00 PM 2110. Rheumatologists on th
- Page 121 and 122: 2:45 PM 2133. Reasons for Decline i
- Page 123 and 124: Session Overview: We are witnessing
- Page 125 and 126: Session Overview: Systemic sclerosi
- Page 127: Oaks, CA, 2 Amgen Inc., San Francis
- Page 131 and 132: 4:30 PM 2198. Association between V
- Page 133 and 134: ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136: THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138: • apply these basic statistics to
- Page 139 and 140: 9:15 AM The ACR/EULAR Definition of
- Page 141 and 142: Immunology, Oslo University Hospita
- Page 143 and 144: 9:15 AM 2239. Factors Associated wi
- Page 145 and 146: Upon completion of this session, pa
- Page 147 and 148: Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150: Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152: ACR Poster Session A Cytokines, Med
- Page 153 and 154: ACR Poster Session A 51. Associatio
- Page 155 and 156: ACR Poster Session A 83. Respirator
- Page 157 and 158: ACR Poster Session A 121. Bone Dens
- Page 159 and 160: ACR Poster Session A 142. The Intra
- Page 161 and 162: ACR Poster Session A 171. Early Pro
- Page 163 and 164: ACR Poster Session A Pediatric Rheu
- Page 165 and 166: ACR Poster Session A 233. Prevalenc
- Page 167 and 168: ACR Poster Session A 266. Subtype S
- Page 169 and 170: ACR Poster Session A 297. Body Weig
- Page 171 and 172: ACR Poster Session A 325. Patient R
- Page 173 and 174: ACR Poster Session A 356. Influence
- Page 175 and 176: ACR Poster Session A 383. Efficacy
- Page 177 and 178: ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360:
A α-galactosylceramide 505 A2A kno
- Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
- Page 363 and 364:
cost-utility 759, 1539 couples 1324
- Page 365 and 366:
fibroblast like synoviocyte 27 fibr
- Page 367 and 368:
impact 1063, 1325 inactive disease
- Page 369 and 370:
methylation 826, 1253, 1489 methylt
- Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378:
Abelson, Abby Goulder, MD Education
- Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382:
ACR Annual Meeting fellowS-in-train
- Page 383 and 384:
NOTES 2010 Program Book 381
- Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
- Page 387 and 388:
Prescription Enbrel ® (etanercept)